These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24122776)

  • 1. A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.
    Wilkins JJ; Dubar M; Sébastien B; Laveille C
    J Clin Pharmacol; 2014 Mar; 54(3):267-78. PubMed ID: 24122776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.
    Horowitz M; Rayner CK; Jones KL
    Adv Ther; 2013 Feb; 30(2):81-101. PubMed ID: 23423907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
    Bolli GB; Owens DR
    Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
    Gómez-Huelgas R; Azriel S; Puig-Domingo M; Vidal J; de Pablos-Velasco P
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):230-40. PubMed ID: 25066229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
    Christensen M; Knop FK; Holst JJ; Vilsboll T
    IDrugs; 2009 Aug; 12(8):503-13. PubMed ID: 19629885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
    Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
    J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
    Trujillo JM; Goldman J
    Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
    Seino Y; Takami A; Boka G; Niemoeller E; Raccah D;
    Diabetes Obes Metab; 2014 Aug; 16(8):739-47. PubMed ID: 24524806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
    Farngren J; Persson M; Ahrén B
    Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
    Lindamood CA; Taylor JR
    Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
    McCarty D; Coleman M; Boland CL
    Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.